MoCRA Compliance: EU vs U.S. Cosmetics Regulation
MoCRA compliance is now a critical issue for cosmetic brands that want to enter the U.S. market from the EU. A CPSR, PIF and EU compliance experience are valuable foundations, but they do not automatically satisfy FDA expectations.
For many years, many cosmetic brands treated the U.S. market as less formally regulated than the European Union. In the EU, the foundation of compliance remains Regulation (EC) No 1223/2009. This regulation requires a Responsible Person, a Product Information File, a safety assessment, compliant labelling and product notification before the cosmetic is placed on the market.
The introduction of the Modernization of Cosmetics Regulation Act of 2022 - MoCRA has significantly changed the regulatory landscape in the United States. The FDA describes MoCRA as the most significant expansion of its authority over cosmetics since the Federal Food, Drug, and Cosmetic Act was passed in 1938. The new obligations include facility registration, product listing, safety substantiation, serious adverse event reporting, records access and product recalls.
For EU brands, this means one thing: a CPSR, PIF and experience with CPNP/SCPN are a strong starting point, but they are not an automatic passport to the U.S. market. The American system operates differently. The EU relies heavily on pre-market compliance control, while the U.S. has strengthened post-market oversight. Brands planning to sell across several jurisdictions should assess compliance as one integrated process, covering cosmetic regulatory compliance in the EU, UK and USA.
1. MoCRA compliance and the role of the Responsible Person
Responsible Person does not mean the same thing in every market
One of the most common mistakes made by brands entering the U.S. market is assuming that the American Responsible Person functions in the same way as the EU Responsible Person. In the EU, the Responsible Person must be established within the European Union. This entity manages product compliance under Regulation 1223/2009, including documentation, safety, labelling, the PIF and responses to market surveillance authorities.
In the U.S., the term Responsible Person has a different meaning. Under MoCRA, it refers to the manufacturer, packer or distributor whose name appears on the cosmetic product label. For this reason, brands should not transfer the EU RP model to the U.S. market without a separate review of the label, distribution structure and post-market obligations. More information on the differences between these responsibility models can be found in Annel's guide: Responsible Person Requirements for Cosmetics in the EU, UK & USA.
For this reason, MoCRA compliance should be reviewed separately from EU Responsible Person obligations. A brand may already have strong EU documentation, but it still needs to confirm who appears on the U.S. label and who manages post-market duties.
U.S. Agent is a separate role
A separate role is the U.S. Agent. This role mainly applies to foreign manufacturing facilities registered with the FDA. The U.S. Agent acts as the FDA's contact point for that facility. It should not be treated as equivalent to the EU Responsible Person. It should also not be treated automatically as the same party as the U.S. Responsible Person.
For brands requiring support with UK/EU Responsible Person services and U.S. Agent or MoCRA support, Annel outlines this scope under Responsible Person Services for Cosmetics in the UK, EU & USA.
The label of a cosmetic product sold in the United States must allow consumers to report adverse events to the Responsible Person. In practice, the label should provide suitable contact details, such as a domestic address, domestic telephone number or electronic contact information. This is not merely a labelling formality. It is part of the cosmetovigilance system.
2. Facility registration and Product Listing in Cosmetics Direct
Why facility data matters for MoCRA compliance
MoCRA introduced an obligation to register facilities that manufacture or process cosmetic products distributed in the United States. Facility registration must be renewed every two years. The FDA may suspend a registration if the relevant conditions relate to serious health risk and potential impact on other products from the same facility.
The second key obligation is Product Listing. The Responsible Person must list each cosmetic product marketed in the United States, together with product and ingredient information. Brands should also update this data annually. The FDA provides information on facility registration and product listing on its page Registration & Listing of Cosmetic Product Facilities and Products. One of the tools available for submitting data is Cosmetics Direct.
From the perspective of an international brand, it is especially important to correctly connect the following data points:
brand - product - manufacturing facility - FEI - product listing - label data
In practice, MoCRA compliance depends not only on documentation, but also on accurate facility, FEI and product listing data. Errors in this chain may lead to delays, regulatory questions or import-related issues.
Having EU documentation is not enough. Operational data must also be consistent with FDA requirements. For brands selling through marketplaces, especially Amazon, there is an additional risk of documentation enforcement by the platform itself. This topic is discussed in more detail in Annel's article Amazon Cosmetic Compliance in the United States: Documentation, Labeling, and Enforcement Risks.
3. Safety substantiation and MoCRA compliance
Why a CPSR is not enough on its own
The EU Cosmetic Product Safety Report is a highly valuable basis for product safety assessment. It contains toxicological data, exposure assessment, ingredient profiles, packaging information, test results and information on product use. However, under MoCRA, the Responsible Person must ensure and maintain records supporting adequate safety substantiation.
The FDA indicates that the law does not prescribe one specific testing method for a cosmetic product or ingredient. However, safety data must come from scientifically robust methods.
Brands should review EU documentation from a U.S. regulatory perspective before relying on it for MoCRA compliance. Particular attention should be given to ingredients permitted in the EU but treated differently in the U.S., colour additives, claims that may shift a product towards drug classification, children's products, eye-area products, SPF products, fragrance ingredients, potential allergens, and complaint or adverse event documentation.
If a brand plans to sell in the EU, UK and USA, ingredient review should not only answer the question "has the product passed CPSR?" It should also assess whether the ingredients are properly evaluated for each jurisdiction.
A strong starting point is a review of Cosmetic Ingredients Compliance in the UK, EU and USA. Brands should also consider a separate Ingredient Risk Assessment for Cosmetics, especially for products containing fragrance substances, colour additives, marketing-active ingredients or ingredients with a changing regulatory status.
4. Colour additives and allergens: high-risk areas for EU brands
Colour additives need separate U.S. review
One of the most practical examples of the difference between the EU and U.S. systems is colour additives. In the United States, all colour additives used in cosmetics must comply with FDA requirements. Some of them also require batch certification, meaning certification of a specific batch by the FDA. The FDA indicates that colour additive violations are a common reason for detention of imported cosmetics offered for entry into the U.S. market.
Detailed information is available on the FDA pages Color Additives and Color Additives and Cosmetics: Fact Sheet.
A European CI number or an indication used in EU documentation does not automatically confirm FDA compliance. In practice, the brand should verify whether a given colour additive is permitted for the intended use in the U.S. It should also check whether batch certification is required and whether raw material documentation is sufficient for import checks or marketplace audits.
The FDA indicates that using an uncertified version of a colour additive that requires certification may cause the product to be considered adulterated under U.S. law.
Fragrance allergens and future labelling rules
Another important area is fragrance allergens. The EU is expanding fragrance allergen labelling obligations, while MoCRA requires the FDA to establish regulations for fragrance allergen labelling. From the perspective of an international brand, the safest strategy is to design labels and documentation in a way that reflects the development of requirements in both the EU and the U.S.
In this context, it is also worth reading Annel's analysis: Why “CPSR Approved” Does Not Mean Your Ingredients Are Compliant in 2026.
5. Cosmetovigilance under MoCRA compliance
15 business days to report an SAE
MoCRA significantly strengthens the U.S. system for monitoring cosmetic product safety. The Responsible Person must report a serious adverse event associated with the use of a cosmetic product in the United States to the FDA within 15 business days. The Responsible Person must include a copy of the product label with the report.
If, within one year of the initial report, the Responsible Person receives additional medical information or other relevant data, this information must also be submitted to the FDA within 15 business days.
This changes the way brands should organise complaints and adverse event handling. A contact form, email inbox or telephone line should not be treated merely as customer service infrastructure. In the United States, they become part of the product safety system.
Therefore, Responsible Person, U.S. Agent and post-market support services should cover not only formal submissions, but also monitoring, risk assessment and incident response procedures. Annel describes this broader support model under Responsible Person Services for Cosmetics in the UK, EU & USA.
Mandatory recall risk
The FDA also now has Mandatory Recall Authority. If the agency determines that a cosmetic product is adulterated or misbranded and there is a reasonable probability that its use or exposure will cause serious adverse health consequences or death, the FDA may order a recall if the Responsible Person does not voluntarily recall the product.
6. MoCRA compliance for borderline products: SPF and claims
Why SPF products need special attention
The biggest risk for EU brands often does not come from the formula itself, but from product classification. SPF products are a good example. In the EU, sunscreen products are generally regulated as cosmetics. In the United States, the FDA regulates sunscreens within the OTC drug products system. This means they are subject to separate FDA requirements, including OTC Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use.
A product classified as a cosmetic in the EU may require assessment under U.S. OTC drug requirements. This may include permitted active ingredients, Drug Facts labelling, permitted dosage forms, product presentation and quality requirements appropriate for this category.
The FDA also publishes questions and answers on current OTC sunscreen requirements on its page Questions and Answers: FDA posts deemed final order and proposed order over-the-counter sunscreen.
Claims can change product classification
A similar risk applies to claims. Claims suggesting treatment, disease prevention, or an effect on the structure or function of the body may move a product outside the cosmetic category.
For this reason, brands should review labels and marketing communications before they print packaging or start sales in the United States. This issue is especially important for brands operating online. Product descriptions, images, marketplace listings and advertising can create claim risk independently of the physical label.
It is worth combining MoCRA analysis with practical marketplace compliance assessment, as discussed in Annel's article Amazon Cosmetic Compliance in the United States.
7. Strategic conclusion: U.S. compliance is not a copy of EU compliance
What EU brands should check before U.S. launch
MoCRA has not created a U.S. system identical to EU Regulation 1223/2009. However, it has created a new reality in which cosmetic brands must prepare for documentation review, data consistency, rapid response to adverse events and greater responsibility after market launch.
For European brands, the safest strategy is not to copy EU documentation into the U.S. system. Instead, brands should prepare a compliance map covering:
- product status in the U.S.;
- claims and OTC drug classification risk;
- Responsible Person data;
- contact details for adverse event reporting;
- facility registration and FEI number;
- Product Listing;
- safety substantiation;
- colour additives;
- high-risk ingredients;
- SAE procedures;
- readiness for recall or corrective actions.
MoCRA does not reduce the value of CPSR and PIF. On the contrary, well-prepared EU documentation can speed up the process of entering the U.S. market. The condition is that the brand adapts it to the American FDA system.
Brands that want to compare EU, UK and U.S. requirements can start by reviewing Annel's cosmetic regulatory compliance services or by downloading educational materials from Free Regulatory Guides for Cosmetics, Packaging and Labelling.
This guide is strategic and educational in nature. It does not replace an individual assessment of a product, formula, label or documentation. If a brand is planning to enter the U.S., EU or UK market, the next step should be a practical compliance review covering documentation, ingredients, claims, labelling and MoCRA obligations.
In this area, Annel provides support through cosmetic regulatory compliance in the EU, UK and USA and dedicated Responsible Person Services for Cosmetics in the UK, EU & USA.
A structured MoCRA compliance review can help identify gaps before products are listed, shipped or sold in the United States.
FAQ
Is MoCRA the same as the EU Cosmetics Regulation?
No. MoCRA does not create a U.S. system identical to EU Regulation 1223/2009. The EU system relies heavily on pre-market compliance, while MoCRA strengthens U.S. post-market oversight, documentation, facility registration, product listing and serious adverse event reporting.
Can an EU CPSR be used for the U.S. market?
A CPSR can be a strong starting point, but it should not be treated as automatic proof of U.S. compliance. Under MoCRA, the Responsible Person must maintain adequate safety substantiation based on scientifically robust methods. Brands should review the documentation from a U.S. regulatory perspective.
Is the U.S. Responsible Person the same as the EU Responsible Person?
No. In the EU, the Responsible Person must be established in the EU and has defined compliance obligations under Regulation 1223/2009. In the U.S., the Responsible Person is the manufacturer, packer or distributor whose name appears on the cosmetic product label.
What is the role of a U.S. Agent under MoCRA?
The U.S. Agent mainly applies to foreign manufacturing facilities registered with the FDA. It acts as the FDA's contact point in relation to that facility. It should not be treated as identical to the EU Responsible Person.
Why are colour additives a risk area for EU brands entering the U.S.?
The U.S. has specific FDA requirements for colour additives. Some colour additives require batch certification. A colour additive that is acceptable in an EU context may still require separate review before use in a cosmetic product sold in the United States.
Are SPF products regulated as cosmetics in the United States?
No. In the United States, sunscreens are regulated within the OTC drug products system. This means that SPF products may require assessment under OTC drug requirements, including active ingredients, Drug Facts labelling and relevant FDA monograph requirements.
When should brands review their MoCRA readiness?
Brands should review MoCRA readiness before printing labels, submitting product listings, launching on Amazon, appointing operational partners or shipping products to the United States.
Need to check whether your EU documentation is ready for the U.S. market?
If your brand plans to sell cosmetic products in the United States, the safest next step is to review the formula, label, claims, Responsible Person data, facility information, product listing requirements and safety substantiation before launch.
Annel can support cosmetic brands with MoCRA gap reviews, ingredient and label risk checks, Responsible Person support, U.S. Agent coordination and cross-market compliance reviews for the EU, UK and U.S. markets.